Incyte’s Opzelura was successful in just one of two parallel phase 3 trials assessing the JAK inhibitor in the skin condition prurigo nodularis. More: Incyte's mixed Opzelura data in prurigo nodularis add uncertainty to potential approval bid: analysts Source: fierce
read moreOtsuka America Pharmaceutical is continuing its work to provide support to and advocate for family caregivers. More: Otsuka debuts new kid-friendly resources about Alzheimer's to ease burden on 'sandwich generation' caregivers Source: fierce
read moreIn 2024, Bayer chief Bill Anderson’s total compensation fell about 21% to 8.84 million euros ($9.6 million). The decline shouldn’t come as a total shock, given that 3.8 million euros of Anderson’s 2023 pay package came from a one-time “indemnity
read moreAstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. More: AstraZeneca touts disease recurrence win, ‘strong trend’ in survival benefit
read moreAstellas Pharma and Yaskawa Electric Corporation formalized a development deal signed last year that will see the two Japanese companies invest 4.5 billion Yen ($30.4 million) into a joint venture to develop an automated cell therapy production system. More: Astellas,
read moreVertex is putting marketing might behind its push into kidney conditions, profiling a patient’s experience of being diagnosed with a genetic disease as part of its commemoration of kidney disease awareness month. More: Vertex puts patient’s story at heart of
read more© 1994 - 2026 B.M. Pharmaceuticals